SecProbe.io

CORRESP
1
filename1.htm

EMAIL: SFeldman@olshanlaw.com

DIRECT DIAL: 212.451.2234

April 24,
2023

VIA EDGAR AND ELECTRONIC MAIL

U.S. Securities and Exchange Commission

Division of Corporation Finance

Mail Stop 3628

100 F Street, N.E.

Washington, D.C. 20549

Attn.: Joe McCann, Esq.

  Office of Life Sciences

 Re: OS Therapies Incorporated

Amendment No. 2 to the Registration Statement

on Form S-1 File No. 333-271034

Ladies and Gentlemen:

On behalf of OS Therapies
Incorporated, a Delaware corporation (the “Company”), we are hereby filing in electronic format through EDGAR with the U.S.
Securities and Exchange Commission (the “SEC”), pursuant to the Securities Act of 1933, as amended, one complete copy of the
Company’s Amendment No. 2 to the Registration Statement on Form S-1 (the “Registration Statement”), including one
complete copy of the exhibits listed as filed therewith.

The Registration Statement responds
to the oral comments received from the staff of the SEC by telephone call with Joe McCann, Esq. with respect to the Company’s Amendment
No. 1 to the Registration Statement on Form S-1 (File No. 333-271034) filed by the Company with the SEC on April 13, 2023.

Courtesy copies of this letter
and the Registration Statement (as marked to reflect changes), together with all exhibits, are being provided by email directly to the
staff for its convenience (attention: Joe McCann, Esq.) in the review of the foregoing documents.

In response to the staff’s
oral comments, disclosure has been added on pages 64 and 73 to (i) explain that the amended and restated development, license and supply
agreement with Advaxis, Inc. (now Ayala Pharmaceuticals, Inc.) (“Advaxis”) was subsequently amended in April 2021 to modify
the payment amounts for Milestones 2 and 3 in consideration for an advance payment by the Company to Advaxis and (ii) clarify that the
Company is required to pay to Advaxis a percentage in the high single digits to low double digits with respect to sublicense fees and
royalties under the terms of such amended agreement. A copy of the first amendment to the amended and restated development, license and
supply agreement with Advaxis is being filed as Exhibit 10.5.1 to the Registration Statement.

*    *     *

April 24, 2023

Page 2

Based on conversations with the
underwriters, the Company and the lead underwriter would like to submit requests for acceleration of effectiveness of the Registration
Statement during the early part of the week of April 24, 2023 in order to meet the Company’s schedule to have the Registration Statement
declared effective by the SEC after the market closes on Wednesday, April 26, 2023. The Company respectfully requests the staff’s
review of the Registration Statement to coincide with this timing.

The remainder of the exhibits to
the Registration Statement have been included in this filing, and we believe the changes that were made to the Registration Statement,
other than the additional disclosures in response to the staff’s oral comments, are minor. Accordingly, we believe that all information,
including the exhibits to the Registration Statement, have been provided to the staff.

Kindly address any comments
or questions that you may have concerning this letter or the enclosed materials to Paul A. Romness, MPH, the Chief Executive Officer of
the Company (tel.: (703) 541-9811), or me (tel.: (212) 451-2234).

    Very truly yours,

    /s/ Spencer G. Feldman

    Spencer G. Feldman

    cc:
    Jimmy McNamara, Esq.

    Paul A. Romness, MPH

    Mr. Keith Moore

    Cavas Pavri, Esq.